Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195))
Publication
, Journal Article
Newby, LK; Marber, MS; Melloni, C
Published in: The Lancet
September 27, 2014
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
The Lancet
DOI
EISSN
1474-547X
ISSN
0140-6736
Publication Date
September 27, 2014
Volume
384
Issue
9949
Start / End Page
1186
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Newby, L. K., Marber, M. S., & Melloni, C. (2014). Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195)). The Lancet, 384(9949), 1186. https://doi.org/10.1016/S0140-6736(14)61726-8
Newby, L. K., M. S. Marber, and C. Melloni. “Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195)).” The Lancet 384, no. 9949 (September 27, 2014): 1186. https://doi.org/10.1016/S0140-6736(14)61726-8.
Newby LK, Marber MS, Melloni C. Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195)). The Lancet. 2014 Sep 27;384(9949):1186.
Newby, L. K., et al. “Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195)).” The Lancet, vol. 384, no. 9949, Sept. 2014, p. 1186. Scopus, doi:10.1016/S0140-6736(14)61726-8.
Newby LK, Marber MS, Melloni C. Erratum: On behalf of the SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: A randomised phase 2 trial (The Lancet (2014) 384 (1187-1195)). The Lancet. 2014 Sep 27;384(9949):1186.
Published In
The Lancet
DOI
EISSN
1474-547X
ISSN
0140-6736
Publication Date
September 27, 2014
Volume
384
Issue
9949
Start / End Page
1186
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences